Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride

(2018) Sven Kohler et al.   DIABETES CARE

Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors

(2018) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype

(2017) Lee Ling Lim et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

(2017) David Z I Cherney et al.   Lancet Diabetes & Endocrinology

Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

(2016) Tim Heise et al.   CLINICAL THERAPEUTICS

Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials

(2016) Kun-Ho Yoon et al.   DIABETES OBESITY & METABOLISM

Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study

(2016) Koutaro Yokote et al.   EXPERT OPINION ON PHARMACOTHERAPY

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Type 2 diabetes via β-cell dysfunction in east Asian people

(2016) Daisuke Yabe et al.   Lancet Diabetes & Endocrinology

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

(2015) Michael Roden et al.   Cardiovascular Diabetology

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

(2015) Rimei Nishimura et al.   Cardiovascular Diabetology

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

(2015) Christopher S. Kovacs et al.   CLINICAL THERAPEUTICS

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians

(2015) Daisuke Yabe et al.   Current Diabetes Reports

Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences

(2015) Linda A Gallo et al.   Diabetes & Vascular Disease Research

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

(2015) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes

(2015) Hans-Ulrich Haering et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Empagliflozin as add-on to metformin in people with Type 2 diabetes

(2015) L. Merker et al.   DIABETIC MEDICINE

Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events

(2015) Daisuke Yabe et al.   Expert Opinion On Drug Safety

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

(2015) Aparna Schweitzer et al.   LANCET

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucose abnormalities in Asian patients with chronic hepatitis C

(2015) Qingyan Bo et al.   Drug Design Development and Therapy

Possible adverse effects of SGLT2 inhibitors on bone

(2015) Simeon I Taylor et al.   Lancet Diabetes & Endocrinology

Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial

(2014) Takashi Kadowaki et al.   ADVANCES IN THERAPY

Renal Control of Calcium, Phosphate, and Magnesium Homeostasis

(2014) J. Blaine et al.   Clinical Journal of the American Society of Nephrology

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

(2014) Ilkka Tikkanen et al.   DIABETES CARE

Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

(2014) Agata Ptaszynska et al.   DRUG SAFETY

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis

(2014) Xu-Ping Yang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Global distribution and prevalence of hepatitis C virus genotypes

(2014) Jane P. Messina et al.   HEPATOLOGY

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States

(2013) Ronald C.W. Ma et al.   Annals of the New York Academy of Sciences

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

(2013) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

NAFLD in Asia—as common and important as in the West

(2013) Geoffrey C. Farrell et al.   Nature Reviews Gastroenterology & Hepatology

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

(2013) Shigeto Kanada et al.   Journal of Diabetes Investigation

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes

(2012) Xilin Yang et al.   ENDOCRINE-RELATED CANCER